At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SPRY ARS PHARMACEUTICALS INC
Market Closed 01-23 16:00:00 EST
10.21
-0.36
-3.41%
盘后10.21
+0.000.00%
19:13 EST
High10.88Low10.21Vol1.47M
Open10.50D1 Closing10.57Amplitude6.34%
Mkt Cap1.01BTradable Cap564.31MTotal Shares98.85M
T/O15.34MT/O Rate2.66%Tradable Shares55.27M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

ARS Pharmaceuticals announces California eligible for neffyinSchools program
TIPRANKS  ·  01-21 21:10
ARS Pharmaceuticals announces California eligible for neffyinSchools program
ARS Pharmaceuticals Down Over 13%, on Pace for Largest Percent Decrease Since March -- Data Talk
Dow Jones  ·  01-13
ARS Pharmaceuticals Down Over 13%, on Pace for Largest Percent Decrease Since March -- Data Talk
Aquestive Stock Slides After FDA Flags Issues With Allergy Drug Application
Benzinga_recent_news  ·  01-10
Aquestive Stock Slides After FDA Flags Issues With Allergy Drug Application
ARS Pharmaceuticals competitor gets FDA deficiency letter, says Raymond James
TIPRANKS  ·  01-09
ARS Pharmaceuticals competitor gets FDA deficiency letter, says Raymond James
ARS Pharmaceuticals Insiders Sold US$1.3m Of Shares Suggesting Hesitancy
Simply Wall St.  ·  2025-12-30
ARS Pharmaceuticals Insiders Sold US$1.3m Of Shares Suggesting Hesitancy
China Approves ARS Pharmaceuticals' Neffy as First Community Use Epinephrine Product
Reuters  ·  2025-12-29
China Approves ARS Pharmaceuticals' Neffy as First Community Use Epinephrine Product
ARS Pharmaceuticals Inc - to Supply Neffy in China by Spring 2026
THOMSON REUTERS  ·  2025-12-29
ARS Pharmaceuticals Inc - to Supply Neffy in China by Spring 2026
ARS Pharmaceuticals - to Receive $4 Mln Regulatory Milestone and Is Eligible to Receive up to $80 Mln in Sales Milestones
THOMSON REUTERS  ·  2025-12-29
ARS Pharmaceuticals - to Receive $4 Mln Regulatory Milestone and Is Eligible to Receive up to $80 Mln in Sales Milestones
Neffy® (Epinephrine Nasal Spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (Anaphylaxis)
THOMSON REUTERS  ·  2025-12-29
Neffy® (Epinephrine Nasal Spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (Anaphylaxis)
ARS Pharmaceuticals Chief Business Officer Justin Chakma Reports Disposal of Common Shares
Reuters  ·  2025-11-15
ARS Pharmaceuticals Chief Business Officer Justin Chakma Reports Disposal of Common Shares
ARS Pharmaceuticals Inc : Leerink Partners Cuts Target Price to $25 From $28
THOMSON REUTERS  ·  2025-11-14
ARS Pharmaceuticals Inc : Leerink Partners Cuts Target Price to $25 From $28
Stock Track | ARS Pharmaceuticals Surges 7.34% Pre-Market on Strong Q3 Revenue, Despite Wider Losses
Stock Track  ·  2025-11-10
Stock Track | ARS Pharmaceuticals Surges 7.34% Pre-Market on Strong Q3 Revenue, Despite Wider Losses
Stock Track | ARS Pharmaceuticals Soars 7.34% Pre-Market on Strong Q3 Results and neffy Sales Growth
Stock Track  ·  2025-11-10
Stock Track | ARS Pharmaceuticals Soars 7.34% Pre-Market on Strong Q3 Results and neffy Sales Growth
Earnings Flash (SPRY) ARS Pharmaceuticals Posts Q3 Net Loss $0.52 a Share, vs. FactSet Est of $0.43 Loss
MT Newswires Live  ·  2025-11-10
Earnings Flash (SPRY) ARS Pharmaceuticals Posts Q3 Net Loss $0.52 a Share, vs. FactSet Est of $0.43 Loss
ARS Pharmaceuticals Q3 EPS $(0.52) Misses $(0.47) Estimate, Sales $32.501M Beat $28.743M Estimate
Benzinga  ·  2025-11-10
ARS Pharmaceuticals Q3 EPS $(0.52) Misses $(0.47) Estimate, Sales $32.501M Beat $28.743M Estimate
ARS Pharmaceuticals Q3 Net Income USD -51.151 Million
THOMSON REUTERS  ·  2025-11-10
ARS Pharmaceuticals Q3 Net Income USD -51.151 Million
ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for Neffy® (Epinephrine Nasal Spray)
THOMSON REUTERS  ·  2025-11-10
ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for Neffy® (Epinephrine Nasal Spray)
Press Release: ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy(R) (epinephrine nasal spray)
Dow Jones  ·  2025-11-10
Press Release: ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy(R) (epinephrine nasal spray)
ARS Pharma Launches GET Neffy® on US for Patients With Severe Allergic Reactions to Improve Access to Neffy (Epinephrine Nasal Spray)
THOMSON REUTERS  ·  2025-11-04
ARS Pharma Launches GET Neffy® on US for Patients With Severe Allergic Reactions to Improve Access to Neffy (Epinephrine Nasal Spray)
ARS Pharmaceuticals resumed with a Buy at Roth Capital
TIPRANKS  ·  2025-11-04
ARS Pharmaceuticals resumed with a Buy at Roth Capital

Introduction

Company Name.
ARS PHARMACEUTICALS INC
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for patients and parents affected by severe allergic reactions. It is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for patients and their caregivers with type I allergic reactions, including anaphylaxis. The company was founded in 2015 and is based in San Diego, California.
Issue price:
--